28. Baysal E, Taysi S, Aksoy N, et al. Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS). Eur Rev Med Pharmacol Sci, 2012, 16(6): 770-774.
[2]
35. Fu Y, Xia Y, Yi H, et al. Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea with or without continuous positive airway pressure treatment. Sleep Breath, 2016, :.
[3]
36. Puckrin R, Iqbal S, Zidulka A, et al. Renoprotective effects of continuous positive airway pressure in chronic kidney disease patients with sleep apnea. Int Urol Nephrol, 2015, 47(11): 1839-1845.
[4]
37. Loube DI, Loube AA, Mitler MM. Weight loss for obstructive sleep apnea: the optimal therapy for obese patients. J Am Diet Assoc, 1994, 94(11): 1291-1295.
[5]
1. Weaver TE, Sawyer A. Management of obstructive sleep apnea by continuous positive airway pressure. Oral Maxillofac Surg Clin North Am, 2009, 21(4): 403-412.
3. Assoumou HG, Gaspoz JM, Sforza E, et al. Obstructive sleep apnea and the metabolic syndrome in an elderly healthy population: the SYNAPSE cohort. Sleep Breath, 2012, 16(3): 895-902.
[8]
4. Botros N, Concato J, Mohsenin V, et al. Obstructive sleep apnea as a risk factor for type 2 diabetes. Am J Med, 2009, 122(12): 1122-1127.
[9]
5. Shpirer I, Rapoport MJ, Stav D, et al. Normal and elevated HbA1C levels correlate with severity of hypoxemia in patients with obstructive sleep apnea and decrease following CPAP treatment. Sleep Breath, 2012, 16(2): 461-466.
[10]
6. Drager LF, Jun J, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes, 2010, 17(2): 161-165.
[11]
7. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest, 2014, 146(5): 1387-1394.
[12]
8. Bjorvatn B, Pallesen S, Gronli J, et al. Prevalence and correlates of insomnia and excessive sleepiness in adults with obstructive sleep apnea symptoms. Percept Mot Skills, 2014, 118(2): 571-586.
10. Iseki K, Tohyama K, Matsumoto T, et al. High Prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertens Res, 2008, 31(2): 249-255.
[15]
19. Foster GE, Hanly PJ, Ahmed SB, et al. Intermittent hypoxia increases arterial blood pressure in humans through a Renin-Angiotensin system-dependent mechanism. Hypertension, 2010, 56(3): 369-377.
[16]
21. Alonso-Fernandez A, Garcia-Rio F, Arias MA, et al. Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax, 2009, 64(7): 581-586.
23. Jin ZN, Wei YX. Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. J Geriatr Cardiol, 2016, 13(4): 333-343.
[19]
11. Jennette JC, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis, 1987, 10(6): 470-472.
[20]
12. Tang X, Xu F, Chen DM, et al. The clinical course and long-term outcome of primary focal segmental glomerulosclerosis in Chinese adults. Clin Nephrol, 2013, 80(2): 130-139.
[21]
13. Lyons OD, Chan CT, Yadollahi A, et al. Effect of ultrafiltration on sleep apnea and sleep structure in patients with end-stage renal disease. Am J Respir Crit Care Med, 2015, 191(11): 1287-1294.
15. Tang R, Yang C, Tao JL, et al. Epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells induced by urinary proteins requires the activation of PKC-alpha and betaI isozymes. Cell Biol Int, 2011, 35(9): 953-959.
[24]
16. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens, 2001, 19(12): 2271-2277.
[25]
17. de Abreu-Silva EO, Beltrami-Moreira M. Sleep apnea: an underestimated cause of resistant hypertension. Curr Hypertens Rev, 2014, 10(1): 2-7.
20. Namtvedt SK, Hisdal J, Randby A, et al. Impaired endothelial function in persons with obstructive sleep apnoea: impact of obesity. Heart, 2013, 99(1): 30-34.
[28]
24. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens, 2012, 26(5): 281-287.
27. Westhoff M, Litterst P. [Obstructive sleep apnoea and oxidative stress]. Pneumologie, 2012, 66(10): 610-615.
[32]
29. Ntalapascha M, Makris D, Kyparos A, et al. Oxidative stress in patients with obstructive sleep apnea syndrome. Sleep Breath, 2013, 17(2): 549-555.
[33]
30. Yamauchi M, Kimura H. Oxidative stress in obstructive sleep apnea: putative pathways to the cardiovascular complications. Antioxid Redox Signal, 2008, 10(4): 755-768.
[34]
31. da Rosa DP, Forgiarini LF, Baronio D, et al. Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver. Mediators Inflamm, 2012, 2012: 879419.
[35]
32. Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace, 2014, 16(9): 1309-1314.
